Fidelity Advisor Biotechnology A holds a quantitatively derived Bronze Morningstar Medalist Rating. The rating reflects that it has scored better than the norm on factors Morningstar research associates with future outperformance relative to category peers.
Fidelity Advisor Biotechnology Fund - Class A FBTAX
- NAV / 1-Day Return 45.89 / −0.02 %
- Total Assets 2.4B
-
Adj. Expense Ratio
0.940%
- Expense Ratio 0.940%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.95%
- Turnover 54%
USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:11 AM GMT+0
Morningstar’s Analysis FBTAX
Will FBTAX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 46.9
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
AbbVie Inc | 14.71 | 324M | Healthcare |
Gilead Sciences Inc | 5.70 | 125M | Healthcare |
Spyre Therapeutics Inc | 3.83 | 84M | Healthcare |
Alnylam Pharmaceuticals Inc | 3.62 | 80M | Healthcare |
Dianthus Therapeutics Inc | 3.55 | 78M | Healthcare |
Cogent Biosciences Inc | 3.25 | 71M | Healthcare |
Oruka Therapeutics Inc | 3.24 | 71M | Healthcare |
Insmed Inc | 3.05 | 67M | Healthcare |
Revolution Medicines Inc Ordinary Shares | 3.00 | 66M | Healthcare |
argenx SE ADR | 3.00 | 66M | Healthcare |
United States